Karyopharm Therapeutics reports preliminary 2025 revenue of $145 mln

Karyopharm Therapeutics

12/01/2026 12:11

Overview

Pharmaceutical company reported preliminary 2025 revenue of $145 mln, with $115 mln from XPOVIO

Company expects transformative Phase 3 trial data in 2026 for myelofibrosis and endometrial cancer

Preliminary Q4 2025 revenue approximately $33 mln, with $32 mln from U.S. XPOVIO

Outlook

Top-line data from Phase 3 SENTRY trial in myelofibrosis expected in March 2026

Phase 3 XPORT-EC-042 trial data in endometrial cancer expected mid-2026

Company anticipates catalyst-rich year with transformative trial outcomes in 2026

Result Drivers

CONSISTENT DEMAND - Demand for XPOVIO remained stable in the competitive multiple myeloma market, with community settings driving 60% of revenue

GLOBAL EXPANSION - Karyopharm expanded global patient access for selinexor with favorable reimbursement in Spain and China

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$33 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Karyopharm Therapeutics Inc is $15.00, about 72.8% above its January 9 closing price of $8.68

Press Release: ID:nPn9dMCtPa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)